Biocept

Biocept R&D / Revenue

The R&D to Revenue Ratio of Biocept (BIOCQ) as of Nov 20, 2026 is 23.83 %. In the previous year, R&D to Revenue Ratio was 8.10 % — a change of 194.22% (higher).

R&D / Revenue

23.83 %

YoY

194.22%

Last updated:

R&D to Revenue Ratio of Biocept is 2022 23.83 % . R&D to Revenue Ratio of Biocept was 2021 8.10 % . It decreases by 194.22% higher compared to the previous year.

The Biocept R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2015
468.85 USD
Jan 1, 2016
84.16 USD
Jan 1, 2017
66.27 USD
Jan 1, 2018
137.54 USD
Jan 1, 2019
84.96 USD
Jan 1, 2020
19.01 USD
Jan 1, 2021
8.10 USD
Jan 1, 2022
23.83 USD
The Biocept R&D / Revenue history
YEARR&D / RevenueYoY
23.83 %+194.22%
8.10 %-57.40%
19.01 %-77.63%
84.96 %-38.23%
137.54 %+107.54%
66.27 %-21.26%
84.16 %-82.05%
468.85 %-86.46%
3,461.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

R&D to Revenue Ratio of Biocept is 23.83 % in 2022.

R&D to Revenue Ratio of Biocept changed from 8.10 % to 23.83 %, representing a 194.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Biocept since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biocept

All Key Metrics — Biocept